R&D Pipeline

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.

Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.

Condition/Disease
Agents
Mechanism
Phase
Partner

Autoimmune Disorders

Atopic Dermatitis

REZPEG (NKTR-358)

Phase 2

Agent(s)

REZPEG (NKTR-358)

+

Autoimmune Disorders

Alopecia Areata

REZPEG (NKTR-358)

Phase 2

Agent(s)

REZPEG (NKTR-358)

+

Autoimmune Disorders

NKTR-0165

Preclinical
Agent(s)

NKTR-0165

+

Immuno-Oncology

NKTR-288

Preclinical
Agent(s)

NKTR-288

+

Hematological Cancer

Large B-Cell Lymphoma

NKTR-255

+ Yescarta® or Breyanzi®

Phase 2/3

Agent(s)

NKTR-255

+ Yescarta® or Breyanzi®

+

Solid Tumors

Maintenance Bladder Cancer

NKTR-255

+ Bavencio®

Phase 2

Agent(s)

NKTR-255

+ Bavencio®

+

Solid Tumors

Advanced Non-small Cell Lung Cancer

NKTR-255

+ C-TIL051

Phase 1

+

Solid Tumors

Stage 2 Non-small Cell Lung Cancer Post Chemoradiation

NKTR-255

+ Imfinzi®

Phase 1/2

Agent(s)

NKTR-255

+ Imfinzi®

+

Hematological Cancer

Relapsed/Refractory Large B Cell Lymphoma

NKTR-255

+ Breyanzi®

Phase 1

+

Hematological Cancer

B-Cell Acute Lymphoblastic Leukemia

NKTR-255

+ CD19/22.BB.z-CAR-T Cell

Phase 1

Agent(s)

NKTR-255

+ CD19/22.BB.z-CAR-T Cell

+